Mantle Cell Lymphoma (MCL)

Oncology·MeSH: Lymphoma, B-Cell, Marginal Zone

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

12 drugs in development·8 companies·8 clinical trials

Drug Pipeline by Phase

Approved(3)

Phase 3(6)

Drug	Company
kte-c19	Kite Pharma, Inc. (KITE)
Orelabrutinib	Merus N.V. (MRUS)
Rocbrutinib	Merus N.V. (MRUS)
Venetoclax	ASTRAZENECA PLC (AZN)
Zanubrutinib	Merus N.V. (MRUS)
zilovertamab	Oncternal Therapeutics, Inc. (ONCT)

Phase 2(3)

Drug	Company
ACP-196	CYTOKINETICS INC (CYTK)
rocbrutinib	NYMOX PHARMACEUTICAL CORP (NYMXF)
Venetoclax	CYTOKINETICS INC (CYTK)

BioSniper tracks 12 drugs in development for Mantle Cell Lymphoma (MCL) across 8 companies.

There are 8 clinical trials targeting Mantle Cell Lymphoma (MCL) tracked by BioSniper.

The estimated prevalence of Mantle Cell Lymphoma (MCL) is approximately 56.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.